<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Seventy-five cases of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in the aged (over 60 years) were analysed for hematological findings, immunological parameters and response to treatment in respect to prognostic significance </plain></SENT>
<SENT sid="1" pm="."><plain>They were diagnosed according to the FAB classification, but patients with <z:e sem="disease" ids="C0151773" disease_type="Disease or Syndrome" abbrv="">hypoplastic marrow</z:e> were included if <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> was evident </plain></SENT>
<SENT sid="2" pm="."><plain>Thirty-four percent of patients with primary acquired <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (<z:chebi fb="8" ids="28618">PARA</z:chebi>) or primary acquired <z:hpo ids='HP_0001924'>sideroblastic anemia</z:hpo> (PASA), and 36% of patients with RA with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) had <z:hpo ids='HP_0005528'>hypoplastic bone marrow</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The positive rates of antinuclear antibody in <z:chebi fb="8" ids="28618">PARA</z:chebi> or PASA, and of rheumatoid factor in <z:chebi fb="8" ids="28618">PARA</z:chebi> or PASA and in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> were higher than those in <z:mpath ids='MPATH_458'>normal</z:mpath> aged controls </plain></SENT>
<SENT sid="4" pm="."><plain>Cellularity of bone marrow was inversely related to the length of survival </plain></SENT>
<SENT sid="5" pm="."><plain>Among the patients with <z:chebi fb="8" ids="28618">PARA</z:chebi> or PASA, survival time was significantly longer in the group of <z:hpo ids='HP_0005528'>hypoplastic bone marrow</z:hpo> than in the group of hyper- or normo-plastic bone marrow, and in the group of good responder to treatment than in the group of poor responder and nontreated patients </plain></SENT>
</text></document>